Carl Icahn happy with Board Representation at Amylin Pharma

February 10th, 2010
| More
Contributed by: Hedge Fund Solutions LLC
Shareholder activist investor Carl Icahn stated on January 25th that he will not seek additional representation on Amylin Pharmaceuticals, Inc.’s (NASDAQ: AMLN) board because enough board members approve of re-nominating two candidates that were appointed last year after a proxy contest with Mr. Icahn’s Icahn Associates and Eastbourne Capital Management LLC. Icahn’s hedge funds currently hold 12,971,328 shares of Amylin or 9.43% of shares outstanding.

Hedge Fund Solutions previously covered AMLN in numerous Catalyst Research Reports, highlighting Icahn’s and Eastbourne Capital’s (12.5%) successful attempt to replace two board members up for election in 2009.
For Detailed Investor Profiles on these Investors, click below:
Eastbourne Capital Management
Icahn Associates (Carl Icahn)
Related People: Alexander J. Denner; Brett Icahn; Carl Icahn; Keith A. Meister*; Rick Barry
Related Entities: Black Bear Hedge Funds; High River Limited Partnership; Icahn Partners; Icahn & Co Inc; Icahn Associates; Icahn Enterprises (formerly American Real Estate Partners); Icahn Fund Ltd; Icahn Partners LP; Robertson Stephens*
Related Article Tags: Shareholder Activists, Corporate Raiders and Proxy Battles; Hedge Fund Resources and Featured Partner News


More Recent Headlines

Nautical Capital Management Unveils New Commodity-Based Strategies

BarCap’s Study Shows Marketing and Communications Spending Up

One Step Backwards?

Castle Hill Asset Management spins-off from Ignis and launches first Hedge Fund

CalSTRS' Efforts Improve Climate Risk Transparency

Hedge Fund Hire Report: RWC Partners, John W. Henry & Co, Harvard’s Endowment, and Moore Capital Management

Hornstein Partners Fund launches with $10 million

BlueGold Capital Denies Responsibility for Oil Sell Off

Phil Falcone makes a killing on new Harbinger Credit Fund

BlueCrest Capital Management to close off BlueTrend Fund to new investors